6.

6.

, ,


5-

298

:
1884
Stevens Lee, (serum)
,
(serum+tonus). (Rapport,
1948) 5-- 5-.
1953, Twarog Page 5-

(Bogdanski, 1956).

:
: , , ,
, , , , .
: , , , , ,
, , , , Alzheimer,
Parkinson, Huntington.

2% . 90%
8% .
,
5-.
5-
.
1% 5-,
.
5,
5- (5-).

6.12 5- () .

5-
. 5- .

(). 5- (5-- ).
5-
5- 24 h.
, ,

.
. 6, p- (PCA). ,
p- (PCA), 1966 (Koa and Weissman). PCPA
.
5-
.

5-. 5-
8--DPAT (8-, ),
5-1 ,



.
.

6.13 5-1

,
8-DPAT
,

5-.

.
Rauwolfia serpentine. , Rauwolfia
. 1940,
Rauwolfia, ( )
- . 1953,
Nathan Kline,
.
. -

299

300

.
,
(, ),

.

,
.

(fenfluramine). ,

.
,
, .
1973, .

6.14 .
,
. ,
,
. (5-1)
(GPCRs: 5-1, 2, 4 5-3).

Fenfluramine (3---,
Pondimin, Ponderax Adifax) Fen-Phen
( phentermine). fenfluramine
1973.
, .
.
1977
.
phentermine
. . (<12
).

Phentemine

. ,

5-1. :
(5-1),
,
(5-1), .
5-1 RU 24969 CP-93,129.

.

301

302

5-1

5-1

-.

RU 24969

CP 93,129

5-1:

.
5-1:
.
5-1 : RU 24969, CP-93,129
(150x -200x )

,
,
, ,
(5- uptake).
5- ,
Na+ .
Na+ , 5- .
Cl- 5-,
. 5-
, +
.
1960,

5- ( ).
,


5-. 1970, Fuller and Wong,
Lilly, (PROZAC),
5-,
.
.

5- (),
.
5- 5- - ( -).

1950
, .
( -), ,
. ,
-, ( -)
( -) (Kato et al, 1986). ,
, .
MAOIs (monoaminoxidase inhibitors)
.

(1982) 5-, 5,6- (5,6-DHT)
5,7- (5,7-DHT),
5-,
5-,
.
.
.

PCP

Control

MDMA

6.15 PCP MDMA 2

. Molliner et al, Ann N.Y. Acad. Sci., 1990.

. PCA (p-),
MDMA (3,4--).
, , 5-. DMA
, , .
PC MDMA
.

303

304

-
, -
-

,
.
6.16

.

5-

,
,
-,
.
5- ,
.
5-,

5-
:
5-1:
(5-1, 5-1/5-1D, 5-1D, 5-1, 5-1F).
:
(<10 nM) 5- 5-CT (5-),
(10-1000 nM) , FMPP,
(>1000 nM) ICS 205-930, DL 72222 .

.
5-2: 3 (5-2, 5-2 5-2C),
(<10 nM)
.
C.

5-3: (<2nM)
ICS 205-930 DL 72222,
5-. 1991 (aricq et al),
-.
5-4: 5-, 5-CT, 5 (5-), .
.
5-5: (5-5A 55B) (1993). , 5-5
5-1 5-CT ,
5-.
5-1,
( 5-1) 5-1,
. O 5-5A
, 5-5B
.
5-6: 1993.
5-4, ,
.
5-7: (Bard et al, 1993).
5-
5-1.
5-4 5-6.
.
:

5-1

5-2

5-1
5-HT1B/5-HT1D
5-HT1D
5-HT1E
5-HT1F
5-HT2A (5-HT2)
5-HT2B (5-HT2F)
5-HT2C (5-HT1C)

5-3
5-4
5-5
5-6
5-7

5-HT5A
5-HT5B

Gi/o

C
Gq/11
K

GS
AC
GS

GS

GS

, 3 .

305

306

6
5-1

5- (5-1, 51/5-1D, 5-1D, 5-1, 5-1F). (<10

nM) 5- 5-CT, .
.

5-1
(<10 nM)

8--DPAT
(
). 8--DPAT,
1982

.
5-1

(,
,
,
, )
,

5-1,

-,

.


,
.
5-1 WAY100-635.

5-1 ,
1992, ,
.
,
5-1 .
5-1 . 5-1
32 390 .

: -355 7
5-1 -
, -355.
51. (d<10nM) (-CYP) , - (DHE)
- , TFMPP 5-,
RU24969 CP94,253.
5-1 .
5-1D 1991,
. 5-1D 5-1 nonA nonB nonC.
. [3]5- 5n 5-1
5-1 (8--DPAT), 5-1
(DHE), 5-1C (mesulergine), .
5-1D,
5-1 5-1F.

. 5-1D 51.
(sumatriptan).
. 5-1
(limbic areas) , , ,
( .
), ,
( ).
5-1 5-1D (substantia
nigra) (globus pallidus),
, ( ) (
).

6.17 . 5 . 5-1
: / 5- (
)
, /
, ( ).

. 5-1
. .
5-1 C,
, G , +
G .
, m1, m2, m4,
D2 .
G ,
.
.
. 5-1
G (7 , 1 , 1
, 3 - 3 ).

307

308

5-1
2- . 5-1
obilka . (1987) (G21) ,
- ,
5-1. 5-1/2-.

.
G
. ,

. . -
, PKA-cAMP .
5-1,
, PKA-cAMP ,
PKC-Ca2+ , ,

.
.
,
(Bmax), ,
(d), G,
.
, 5-1,
(down-regulation)
(desensitization) .
, .
(up-regulation)
(upersensitization) .
, 5,7-- (5,7DHT). , 5-1 ,
, 5-1
,
5- up-regulation .
5-1 :
5-1 (
5-1),
( )
5-1.
, 5-1 .
.
, (max)
5-1 .
Alzheimer
5-1 .
untington 50%
5-1D .

. 5-1
(firing)

5-. 5-1
G +, .
+ ,
. (
),
. . Ca2+ Ca2+,
Ca2+- 5-
.

6.18 5-1 G +.
+ :

- Ca2+ Ca2+ .

5-1

5-1

,
,


.
5-1
,


,

309

310

. 51 5- .
5-1, G
GIRK (G protein-coupled, inwardly rectifying K+)
+ , 5-1
5-
GIRK- , Ca2+
G .
5-1 , ,
.
5-1
.
,
(, , .)
, . 51 .
5-1
(
, ), (
,
) (
). 5-1
( 5-1,
)
.
5-1 5-1
.
5,7-DHT
, .
5-1 .
5-, , 5-1
,
. 5-1
( )

.
5-1
(working memory),
. .
8--DPAT ,
(passive avoidance), ,
. , .
5-1
.
5-1
. , , ,
( buspirone
BuSparR) .
(2-3 )
.

311

, , - .
,

. 5-1
,
,

.
.

(long-term
administration).

. ,
. ,
5-1
, 5 . ,

,
5-1. ,
5-1 5-1
( )
.

5-1

5-1

() 5-1
() 5-
6.19 , 5-1
,
5- . ,
5-1

5-1.

312

Buspirone, Buspar

generalized anxiety disorder (GAD).
1986 Bristol-Myers Squibb (BMS).
.
5-1
, .
.
5-1
. isolation induced stress
,
5-1 , .
learned helplessness,
5- ,
5-1
( 5-)
5-1 5-.
5-1D 5-1
( GR-43175),
. ,
, .

, (
). 5- ()
. ,
(Substance P, CGRP: calcitonin gene-related peptide).
SP CGRP ,

.
5-1D ,

, ,
.

5-1

5-1

5-1

6.20 ,
( ). 5-

. , SP
CGRP.
(
), .

15%
1 .
34% 51%

.
,
.

Ebers,
1500 .. . 200 ..,

.

313

314

,
, 7.000 ..
,

.
.
William Harvey
17

(dura matter)
, .
5-2

3 : 5-2 (
5-2), 5-2 ( 1992
5-2F) 5-2C (
5-1C).
, , ,
C.
,
. ,
DOM, DOI, DOB .
,
.

.
, , 5-2
, .

. ,
,
. 5-2
(emergency receptors)

.

50% (max),
(3) .
5-2
. ( 50%)
, 5-2
.
.
, , , .
5-2.
( LSD)
5-2 ,
. 5-2
(Obsessive Compulsive
Disorder, OCD). ,
5- (SRI)
, .
agomelatine 5-2C.
Novartis 2012. Valdoxan
.

315

316

Agomelatine
(MT1 MT2 Ki =
0.12nM)) 52C (Ki = 631nM).

, , ,
,
.

.
.

5-3

, ,
G,
. 5-3
G, ,
. fast responding receptors
, 5-, slow responding receptors
, ,
G,
.
5-3 (1991),
, ,

5-3 .
5-3,
, , , .
meta--.
5-3
, , , ,

(motor nucleus of the vagus nerve),

(area postrema).
5-3
,
. 5-3
,
. 5-3 ,
, ,

.
5-3.
. 53 .
5-3

( ).

5- .
5-3 (vagus nerve),
(area postrema)
. 5-3 .

317

318

6.21 .

5-3.
- ( )
, ,
. ,
-
.
5-3 ,
, 5-3
5- ,
. ,
5-3, GA.
(nucleus accumbens).
5-3 ,
.
5-3
. 5-3, 51,
.
5-3
, ,
(DZ).
, BDZ 5- ,
.
5-, .
5-3
,

5-3
. 5-3

.
5-4

5-4
[3]GR113808
(1995) (1997).
5- ,

.

5-4. ,
in vivo. 5-4 5- ( 5-, 5-3),
U1, U8, RS66331, zacopride cisapride ( 5-3).
5-4 GR113808 (
, in vitro), GR125487 SB204070 (
5-4, , in
vivo), SOZ205557, RS23597 tropisetron (
5-3).
5-4 , in vivo,
.
, [ 3H]GR113808
[125I]SB207710, 5-4
. 5-4 (100-400 fmoles/mg prot.)
: (olfactory tubercule),
(cortex frontal), (globus pallidus), Calleja, ,
, .
5-4 Gs .
cAMP,
().
+,
-
Ca2+. (
).
5-4 ( 1-2 sec)
+ 2 .
+
. 5-4
,
.

319

320

6.22 + 5-4.
5-4 ( 1-2 sec) + 2 ,
cAMP
. R. M. Engen et al, TiPS, 1995, 16, 391-397.

5-4
. ,
5-4 .
,
5-4 .
5-4 .
in vitro , in vivo,
5-4 ,
5-4,
Parkinson
, .
Alzheimer
: -control 5-4 2,3 fmoles/mg prot.,
lzheimer 0,78 fmoles/mg prot.
( )
, 54 ,
5-4 .
5-4 ,
andel plysia californica, 5-
cAMP, + ( +),
.
O 5-4 ,
5-4
,
.

ifa E. and Fillion G., 5-hydroxytryptamine receptors, Pharmacol. Rev., 1992, 44, 401458.
Baxter G. et al, 5-HT2 receptor subtypes: a family re-united? TiPS, 1995,16, 105-109
Blier P., Bergeron R. and de Montigny C., Selective activation of postsynaptic 5-HT1A
receptors induces rapid antidepressant response, Neuropsychopharmacology, 1997,
16(5), 333-338
Boess FJ, and Martin IL., Molecular biology of 5-HT receptors, Neuropharmacology,
1994, 33, 275-317

321

322

Boess FJ. et al, Ultrastructure of the 5-hydroxytryptamine3 receptor, J. Neurochem., 1995,

64, 1401-1405
Buhot M.C, Serotonin receptors in cognitive behaviors, Curr. Opin. Neurobiol., 1997, 7(2),
243-254
Delgado PL., and Moreno FA., Hallucinogens, serotonin and obsessive-compulsive
disorder, J. Psychoactive Drugs, 1998, 30, 359-366
Engen R. et al, Central 5-HT4 receptors, TiPS, 1995,16, 391-397
Fanburg B.L. and Lee S.L., A new role for an old molecule: serotonin as a mitogen, Am. J.
Physiol., 1997, 272(5 Pt1): L795-L806
Fozard JR., and Kalkman HO., 5-Hydroxytryptamine and the initiation of migraine: new
perspectives, Naunyn-Schmiedebergs Arch. Pharmacol.,1994, 350, 225-9
Gilman P.K., The serotonin syndrome and its treatment, J. Psychopharmacol., 1999, 13,
100-9
Gthert M., et al, Genetic variation in human 5-HT receptors: potential pathogenetic and
pharmacological role, Ann. N.Y. Acad. Sci., 1998, 861, 26-30
Grant K.A., The role of 5-HT3 receptors in drug dependence, Drug and Alcool
Metabol.,1995, 38, 155-171
Hagan RM., Kilpatrick GJ., and Tyers MB., Interactions between 5-HT3 receptors and
cerebral dopamine function: implications for the treatment of schizophrenia and
psychoactive substance abuse, Psychopharmacology, 1993, 112, S68-75
Hartig P. et al, Alignment of receptor nomenclature with the human genome classification
of 5-HT1B and 5-HT1D receptor subtypes, TiPS, 1996, 17, 103-105
Hindle AT., Recent developments in the physiology and pharmacology of 5hydroxytryptamine, Br. J. Anaesth., 1994, 73, 395-407
oyer D. et al, International union of pharmacology classification of receptors for 5hydroxytryptamine (serotonin), Pharmacol. Rev., 1994, 46, 157-203
Hoyer D, et al, 5-Ht receptor classification and nomenclature: towards a harmonization
with the human genome, Neuropharmacology, 1997, 36(4-5), 419-428
Jackson . and Yakel J., The 5-HT3 receptor channel, Annu. Rev. Physiol., 1995, 57, 44768
Johnson K.W., et al, Serotonin in migraine: theories, animal models and emerging
therapies, Prog. Drug Res., 1998, 51, 219-44
Jolas T. et al, Are postsynaptic 5-HT1A receptors involved in the anxiolytic effects 5-HT1A
receptor agonists and in their inhibitory effects on the firing of serotonergic neurons
in the rat? J. Pharmacol. Exper. Ther., 1995, 272, 920-929
Kirk E.E. et al, Serotonergic receptors as targets for pharmacology, J. Neurosci. Nurs.,
1997, 29(3), 191-197
Kroeze W.K, and Roth B.L., The molecular biology of serotonin receptors: therapeutic
implications for the interface of mood and psychosis, Biol. Psychiatry, 1998, 44,
1128-42
Martin GR, and Humphrey PP., Receptors for 5-Hydroxytryptamine: current perspectives
on classification and nomenclature, Neuropharmacology, 1994, 33, 261-73
Martin GR., et al, The structure and signaling properties of 5-HT receptors: an endless
diversity? TiPS, 1998, 19, 2-4
Morin L.P., Serotonin and the regulation of mammalian circadian rhythmicity, Ann. Med.,
1999, 31, 12-33
Olmo E. Et al, Ontogenetic development of 5-HT1D receptors in human brain: an
autoradiographic study, Eur. J. Neurosci.,1996, 8, 53-60
Parker R. et al, Allosteric modulation of 5-HT3 receptors: focus on alcohols and
anaesthetic agents, TiPS, 1996, 17, 95-99

Pauwels PJ., 5-HT1B/1D receptor antagonists, Gen. Pharmacol., 1997, 29(3), 293-303
Peroutka SJ, and Howell TA., The molecular of G protein-coupled receptors: focus on 5Hydroxytryptamine receptors, Neuropharmacology,1994, 33, 319-24
Roila F. and Del Favero A., Antiemetics revisited, Cuur. Opin. Oncol., 1997, 9(4), 321326
Seguin L. et al, The endogenous cerebral tetrapeptide 5-HT-moduline reduces in vivo the
functional activity of central 5-HT1B receptors in the rat, Neurosci. Res., 1997, 27,
277-280
Uphouse L., Multiple serotonin receptors: too many, not enough, or just the right number?
Neurosci. Biobehav. Rev., 1997, 21, 679-698
Van den Wyngaert I., et al, Cloning and expression of a human serotonin 5-HT4 receptor
cDNA, J. Neurochem., 1997, 69(5), 1810-1819
Whitaker-Azmitia PM., et al, Serotonin as a developmental signal, Behav. Brain Res.,
1996, 73, 19-29
Arnsten AF., Catecholamine regulation of the prefrontal cortex, J. Psychopharmacol.,
1997, 11, 151-162
Bremner JD., et al, Noradrenergic mechanisms in stress and anxiety: II. Clinical studies,
Synapse, 1996, 23, 39-51
Bylund DB., Pharmacological characteristics of alpha2-adrenergic receptor subtypes, ANN.
N.Y. Acad. Sci., 1995, 763, 1-7
Cooper JR., Bloom FE., Roth RH., ,
, 1996, ( 9: , .163207)
Cotecchia S., et al, Molecular mechanisms underlying the activation and regulation of the
alpha1B -adrenergic receptor, Biochem. Soc. Trans., 1996, 24, 959-963
Cotecchia S., et al, Signalling and regulation of the alpha1B-adrenergic receptor, Biochem.
Soc. Trans., 1995, 23, 121-125
Day H.E.W., Campeau S., Watson S.J. and Akil H., Distribution of 1a, 1b, and 1dadrenergic receptor mRNA in the rat brain and spinal cord, J. Chemical
Neuroanatomy, 1997, 13, 115-139
De Ponti F., Pharmacological criteria for the detection of beta3-adrenoceptors, Trends
Pharmacol. Sci., 1997, 18, 52-53
Dinan TG., Noradrenergic and serotonergic abnormalities in depression: stress-induced
dysfunction? J. Clin. Psychiatry, 1996, 57 (Suppl4), 14-18
Frazer A., Pharmacology of antidepressants, J. Clin. Psychopharmacol., 1997, 17(2), 2S18S
Garcia-Sainz JA., 1-adrenergic action: receptor subtypes, signal transduction and
regulation, Cell Signal., 1993, 5, 539-545
Garcia-Sainz JA., Adrenaline and its receptors: one hundred years of research, Arch. Med.
Res., 1995, 26, 205-212
Garcia-Sainz JA., Vazquez-Prado J., and del Carmen Medina L., 1-adrenoceptors:
function and phosphorylation, Eur. J. Pharmacology, 2000, 389, 1-12
Goldstein DS., Catecholamine receptors and signal transduction. Overview, Adv.
Pharmacol., 1998, 42, 379-390
Grace AA., Gerfen CR., Aston-Jones G., Catecholamines in the central nervous system.
Overview, Adv. Pharmacol., 1998, 42, 655-670
Graham RM., et al, Characterization of 1-adrenergic receptor subtypes, Pharmacol.
Commun., 1995, 6, 15-22
Graham RM., et al, alpha1-adrenergic receptor subtypes. Molecular structure, function, and
signaling, Circ. Res., 1996, 78, 737-749

323

324

Grunberg SM., Future of the management of emesis, Support Care Cancer, 1994, 2, 301303
Guarino RD., Perez DM., Piascik MT., Recent advances in the molecular pharmacology of
the alpha1 -adrenergic receptors, Cell Signal, 1996, 8, 323-333
Hein L., Kobilka BK., Adrenergic receptor signal transduction and regulation,
Neuropharmacology, 1995, 34, 357-366
Hieble JP., and Bond RA., New directions in adrenoceptor pharmacology, Trends
Pharmacol. Sci., 1994, 397-399
Hieble JP., Bondinell WE., Ruffolo RR. Jr, Alpha- and beta-adrenoceptors: from the gene
to the clinic. 1. Molecular biology and adrenoceptor subclassification, J. Med.
Chem., 1995, 38, 3415-3444
Hieble JP., et al, International Union of Pharmacology. X. Recommendation for
nomenclature of alpha1-adrenoceptors: consensus update, Pharmacol. Rev., 1995, 47,
267-270
Hieble JP., Ruffolo RR Jr., Subclassification and nomenclature of alpha 1- and alpha 2adrenoceptors, Prog. Drug Res., 1996, 47, 81-130
Kamibayashi T., Harasawa K., Maze M., Alpha2- adrenergic agonists, Can. J. Anaesth.,
1997, 44(5 Pt2), R13-R22
Leon M., Catecholaminergic contributions to early learning, Adv. Pharmacol., 1998, 42,
961-964
Leonard BE., Noradrenaline in basic models of depression, Eur. Neuropsychopharmacol.
1997, 7 (Suppl1), S11-S16
Leonard BE., The role of noradrenaline in depression: a review, J. Psychopharmacol.,
1997, 11(4Suppl), S39-S47
Lipworth BJ., Clinical pharmacology of beta3-adrenoceptors, Br. J. Clin. Pharmacol.,1996,
42, 291-300
McEwen BS., Sapolsky RM., Stress and cognitive function, Curr. Opin. Neurobiol., 1995,
5, 205-216
McGaugh JL., Cahill L., Roozendaal B., Involvement of the amygdala in memory storage:
interaction with other brain systems, Proc. Natl. Acad. Sci. (USA), 1996, 93, 1350813514
McKinnon AC., Spedding M., Brown CM., 2-adrenoceptors: more subtypes but fewer
functional differences, Trends Pharmacol. Sci., 1994, 15, 119-123
Mersmann HJ., Overview of the effects of beta-adrenergic receptor agonists on animal
growth including mechanisms of action, J. Anim. Sci., 1998, 76, 160-172
Mersmann HJ., Species variation in mechanisms for modulation of growth by betaadrenergic receptors, J. Nutr., 1995, 125 (Suppl6), 1777S-1782S
Michel MC., Kenny B., Schwinn DA., Classification of alpha1-adrenoceptor subtypes,
Naunyn Schmiedebergs Arch. Pharmacol., 1995, 352, 1-10
Milligan G. and Bond RA., Inverse agonism and the regulation of receptor number, Trends
Pharmacol. Sci., 1997, 18, 468-474
Milligan G., Svoboda P., Brown CM., Why are there so many adrenoceptor subtypes?
Biochem. Pharmacol., 1994, 48, 1059-1071
Minneman K.P., and Esbenshade T.A., 1-adrenergic receptor subtypes, Annu. Rev.
Pharmacol. Toxicol., 1994, 34, 117-133
Nicholas AP., Hokfelt T., Pieribone VA., The distribution and significance of CNS
adrenoceptors examined with in situ hybridization, Trends Pharmacol. Sci., 1996,
17, 245-255
Pepperl D.J., and Regan J.W., Adrenergic receptors, in Handbook of receptors and
channels, Ed. by Stephen Peroutka, CRC Press, 1994

Potter PC., Genetic abnormalities of the human beta2-adrenergic receptor, Clin. Exp.
Allergy, 1995, 25, 596-598
Potter WZ., Adrenoceptors and serotonin receptor function: relevance to antidepressant
mechanisms of action, J. Clin. Psychiatry, 1996, 57 (Suppl4), 4-8
Rohrer DK. and Kobilka BK., G protein-coupled receptors: functional and mechanistic
insights through altered gene expression, Physiol. Rev., 1998, 78, 35-52
Ruffolo RR. Jr, Bondinell W., Hieble JP., Alpha- and beta-adrenoceptors: from the gene to
the clinic. 2. Structure-activity relationships and therapeutic applications, J. Med.
Chem., 1995, 38, 3681-3716
Sambunaris A., et al, Development of new antidepressants, J. Clin. Psychiatry, 1997, 58
(Suppl6), 40-53
Sirvi J., and MacDonald E., Central 1-adrenoreceptors: Their role in the modulation of
attention and memory formation, Pharmacology & Therapeutics, 1999, 83, 49-65
Smiley RM., Finster M., Do receptors get pregnant too? Adrenergic receptor alterations in
human pregnancy, J. Matern. Fetal Med., 1996, 5, 106-114
Stanford SC., Central noradrenergic neurons and stress, Pharmacol. Ther., 1995, 68, 297242
Strosberg AD., Association of beta3-adrenoceptor polymorphism with obesity and
diabetes: current status, Trends Pharmacol. Sci., 1997, 18, 449-454
Strosberg AD., Function and regulation of the beta3-adrenoceptor, Trends Pharmacol. Sci.,
1996, 17, 373-381
Strosberg AD., Structure and function of the beta3-adrenergicreceptor, Annu. Rev.
Pharmacol. Toxicol., 1997, 37, 421-450
Strosberg AD., Structure, function, and regulation of the three beta-adrenergic receptors,
Obes. Res., 1995, 3 (Suppl4), 501S-505S
Tobin AB., Phosphorylation of phospholipase C-coupled receptors, Pharmacol. Ther.,
1997, 75, 135-151

325